clinical trial · NCT00688688
Study to Test the Long Term Safety and Efficacy of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder
Urinary Bladder, OveractiveMirabegronTolterodinePlacebo to MirabegronPlacebo to Tolterodine
brief summary
The study is intended to test the safety, tolerability, efficacy of two doses of long term once daily (qd) treatment of Mirabegron in patients with symptoms of overactive bladder and secondly to compare these with active comparator.
started
Apr 25, 2008
primary completion
May 6, 2010
completion
May 6, 2010
last updated
Nov 20, 2024
detailed description
Patients who completed 178-CL-046 (NCT00689104) or 178-CL-047 (NCT00662909) or new patients could be enrolled in this study if eligible.
official title
A Randomized, Double-Blind, Parallel Group, Active Controlled, Multi-center Long-term Study to Assess the Safety and Efficacy of the Beta-3 Agonist Mirabegron (YM178) 50 mg qd and 100 mg qd in Subjects With Symptoms of Overactive Bladder
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol